Canada markets closed

IQVIA Holdings Inc. (IQV)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
231.49-2.90 (-1.24%)
At close: 4:03PM EDT

231.49 0.00 (0.00%)
After hours: 5:36PM EDT

Full screen
Trade prices are not sourced from all markets
Previous Close234.39
Bid232.14 x 900
Ask231.49 x 800
Day's Range231.28 - 235.86
52 Week Range128.52 - 237.47
Avg. Volume959,195
Market Cap44.368B
Beta (5Y Monthly)1.46
PE Ratio (TTM)110.23
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    U.S. District Court Issues Favorable Decision for IQVIA Against Veeva

    IQVIA (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the U.S. District Court of New Jersey issued a favorable decision in its litigation with Veeva Systems, Inc. (NYSE:VEEV). The Court ruled on IQVIA’s motion for sanctions, finding Veeva engaged in massive destruction of evidence, engaged in a cover-up of its wrong-doing, and repeatedly lied about its actions. The court sanctioned Veeva five separate times in the decision to punish Veeva for its violations of rules in the litigation, including multiple adverse jury instructions, limitations on the use of evidence at trial and an award of legal fees and costs. Specific language from the decision includes:

  • Business Wire

    IQVIA’s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug

    IQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc – a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies – to support the launch of AZSTARYS™, which was approved by the U.S. FDA on March 2, 2021. AZSTARYS is the first and only product containing a dexmethylphenidate (d-MPH) oral prodrug for the treatment of attention deficit hyperactivity disorder (ADHD) symptoms in patients aged six years and older.

  • Business Wire

    Global Medicine Spending to Reach $1.6 Trillion in 2025 Excluding Spending on COVID-19 Vaccines, According to IQVIA Institute for Human Data Science Study

    Global spending on medicines — using invoice price levels — is expected to grow at 3-6 percent CAGR through 2025 to reach about $1.6 trillion by 2025, excluding spending of COVID-19 vaccines, according to a new research report The Global Spending and Usage of Medicines released by the IQVIA™ Institute for Human Data Science. The total cumulative spending on COVID-19 vaccines through 2025 is projected to be $157 billion, largely focused on the initial wave of vaccinations to be completed by 2022. In subsequent years, booster shots are expected to be required on a biannual basis as the durability of immunity and the continued emergence of viral variants make an endemic virus the most likely outcome.